Opus Genetics (IRD) Capital Expenditures (2010 - 2019)

Opus Genetics (IRD) has 9 years of Capital Expenditures data on file, last reported at $5617.0 in Q4 2019.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $5617.0 in Q4 2019; TTM through Dec 2019 was $25000.0, a 36.26% decrease from a year earlier, with the FY2019 full-year figure at $25000.0, down 36.26% from the prior year.
• Capital Expenditures for Q4 2019 stood at $5617.0, down from $6202.0 in the prior quarter.
• Over the last five years, Capital Expenditures for IRD reached as high as $53799.0 in Q4 2017 and fell as low as $403.0 in Q4 2016.
• Historically, Capital Expenditures has averaged $11686.7 across 5 years, with a median of $5106.5 in 2016.
• Across the five-year window, Capital Expenditures slumped 98.13% in 2016 and soared 13249.63% in 2017, its largest moves.
• Year by year, Capital Expenditures stood at $9803.0 in 2015, then slumped by 95.89% to $403.0 in 2016, then surged by 13249.63% to $53799.0 in 2017, then slumped by 33.58% to $35731.0 in 2018, then sank by 84.28% to $5617.0 in 2019.
• Per Business Quant data, the three most recent Capital Expenditures figures were $5617.0 in Q4 2019, $6202.0 in Q2 2019, and $13181.0 in Q1 2019.